City Sanofi Financial News

In this article

, a 22-employee company with operations in Shanghai and San Diego, had been working on its own therapies. By poring over the patents from Western companies, the biotech found clues to improve its drug candidates.Within months, GluBio had made tweaks that produced more powerful and targeted therapies.

Subscribe to enjoy similar stories. Wockhardt Ltd that built its name as a maker of generic drugs is shifting its focus in the US market to developing new antibiotics, turning away from generics and entering a space largely vacated by Big Pharma in recent years. The company is working on new antibiotics and has identified segments for a push into biosimilar drugs, chairman Habil Khorakiwala said, in the wake of promising results shown by Zaynich, an antibiotic it developed in-house.

Subscribe to enjoy similar stories. L’Oreal will sell part of its stake in Sanofi back to the French pharmaceutical company for 3 billion euros ($3.11 billion), bolstering its balance sheet while the beauty industry is undergoing a slowdown. The deal will diversify the French beauty giant’s funding sources and represent a big chunk of Sanofi’s 5 billion-euro buyback program set out last week, the companies said Monday.

Sanofi Healthcare India, a subsidiary of global healthcare giant Sanofi, has leased 270,000 sq ft in Hitech City, Hyderabad.

Emcure Pharmaceuticals on Thursday reported a 38.2% year-on-year (YoY) increase in net profit to Rs.202 crore in Q2FY25 led by strong performance of domestic and international business The Pune-based drug maker posted Rs 145.8 crore in the same period last year.

Sanofi Consumer Healthcare India Ltd for an aggregate of up to Rs 2,983 crore. The development follows Sanofi and Clayton, Dubilier & Rice (CD&R) entering into exclusive negotiations whereby CD&R Group has agreed to acquire a controlling stake in Opella, which holds a 60.4% stake in Sanofi Consumer Healthcare India. The offer is made at a price of Rs 4,982.05 per share, aggregating to a total consideration of up to Rs 2,983.23 crore, according to the offer letter by Citigroup Global Markets India, the manager of the transaction, shared on BSE by Sanofi Consumer Healthcare India.

Subscribe to enjoy similar stories. Ashish Kacholia, ace investor and director of Lucky Investment Managers Pvt Ltd, recently walked away from five stocks. If you are an investor in the Indian stock markets, chances are you've heard of him.

Panacea Biotec on Tuesday said it has entered into a settlement with Sanofi Healthcare India Private Limited in a patent infringement litigation over hexavalent vaccine. Under the terms of settlement agreement, Sanofi has agreed that at present it would not commercially launch its fully liquid hexavalent vaccine Shan6 in India and shall also withdraw the opposition filed against Panacea Biotec’s patent IN 272351 on hexavalent vaccine before the Indian Patent Office. In turn, Panacea Biotec has agreed to forgo its claim for damages and rendition of accounts in the proceedings against Sanofi.

French drugmaker Sanofi plans to invest ₹400 million (about ₹3,600 crore) over the next six years to expand its global capability centre (GCC) in Hyderabad by increasing the headcount and further developing the facility. Of the total, ₹100 million will be invested by the end of 2025. Over the next two years, Sanofi plans to more than double the headcount at the Hyderabad GCC to 2,600 employees, making the centre the largest of its four hubs globally. The company employs about 1,000 people in Hyderabad. The Hyderabad GCC will support Sanofi's global operations spanning commercial, manufacturing, supply chain research and development (R&D) and digitalisation. The GCC in India will help the company bring some of outsourced functions in-house, giving it more control over critical operations like manufacturing, commercial and R&D.

Stocks that are trading heavily or have substantial price changes on Tuesday: Assured Guaranty, Kymera rise; BP, Helen of Troy fall

₹65 to ₹68 per share of face value of ₹10 each. The SME (Small and Medium enterprises) will open for subscription for investors on Wednesday, 19 June 2024.The subscription period for the Durlax Top Surface IPO begins on June 19, 2024, and ends on June 21, 2024.

Hawaii's attorney general says a court has ordered the manufacturers and distributors of the blood thinner Plavix to pay the state a combined $916 million after finding the companies failed to disclose the efficacy and safety of the medication

U.S. stocks coasted to the close of another winning week with a quiet, mixed finish

Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will receive $500 million in upfront payments as well as a further $700 million if all development, regulatory and launch milestones are met, according to a statement Friday. Novavax, which will receive tiered royalties on any vaccine sales, said Sanofi is also taking a minority equity stake of about 5% in the US company.

₹7083 crore, but the drop in Ebitda was steeper at nearly 12% to ₹1,784 crore. DRL’s US sales dropped 2.2% sequentially, driven by lower Revlimid sales and price-erosion in a few other molecules. Some analysts reckon DRL’s US revenue from Revlimid, a key product, may well have peaked in FY24.

Also read: Serum Institute to receive up to $30 mn from global network to make pandemic vaccines "An agreement has been signed under which Bharat Biotech will procure drug substances for manufacturing oral polio vaccines to be supplied within India and globally. This will contribute to supply security of oral polio vaccines. With this partnership, the capacity of BBIL to manufacture Oral Polio Vaccine (OPV) has increased to 500 million doses every year," said a statement by the Health Ministry.

Read the full story here.)Sensex Today Live : ABFRL, Infosys, RIL, Airtel, Vi, Sanofi, HAL, Aurobindo Pharma, are some stocks likely to be in focus on Tuesday, April 2.Sensex Today Live : The Sensex and Nifty 50, India's primary stock market indices, are anticipated to commence Tuesday's trading session on a downbeat note, influenced by unfavorable cues from the global markets. The Gift Nifty trends also suggest a gap-down opening for the Indian benchmark index, trading around the 22,550 level, nearly 50 points lower than the previous close of Nifty futures.On the previous trading day, Monday, the domestic equity benchmark indices concluded the session with a half percent increase, setting new record highs, with the Nifty 50 closing above the 22,400 mark.

Mint in an interview. He added that this is an important region that the company is focusing on and has a lot more plans to further double down in India. As part of its strategy, the company will introduce some new products, including its pre-mix insulin drug Soliqua, and Xenpozyme, which is used to treat late-onset pompe disease.

₹426 crore ($51 million) as per IQVIA MAT February 2024. Sanofi said it will continue to own, manufacture and import them to the country. M.V.

Goldman Sachs, which coined the term BRICS, has come up with monikers for stocks driving stock market rallies in Europe and Japan, alongside the US' 'Magnificent Seven' — Apple, Microsoft, Alphabet, Amazon, Tesla, Meta and Nvidia. European 'Granolas' — GSK, Roche, ASML, Nestle, Novartis, Novo Nordisk, L'Oreal, LVMH, AstraZeneca, SAP and Sanofi — are a more diversified grouping than the US tech constellation. Yet, the 11 companies are still tightly packed around lifestyle, with the occasional presence of software.

Once a stock-market trend has been identified and named—think FAANG or the Magnificent Seven—the headiest gains are typically past. But riding a trend after it has been named can deliver market-beating returns for another year or so before the trade loses momentum and gives back some of the gains. To study the performance of named stock-market trends, my research assistants (Matthew Rickard and Camila Marín Builes) and I did a deep-dive on eight named trends over the past 10 years that were popularized by the mainstream media and covered by more than three such organizations.